Tag: Eli Lilly
Zepbound, Shaq launch national OSA awareness campaign
June 10, 2026HME News Staff
INDIANAPOLIS – Eli Lilly and Company has announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight into his diagnosis and treatment journey with Zepbound (tirzepatide). After years of dismissing fatigue, loud snoring and difficulty focusing as normal parts of his life, O'Neal learned they were actually symptoms of moderate-to-severe OSA. Moderate-to-severe OSA is a serious...
Lilly’s investigational GLP-1 reduces AHI by up to 36 events per hour in OSA patients
June 8, 2026HME News Staff
INDIANAPOLIS – Eli Lilly, the maker of Zepbound and Foundayo, has announced positive results from Phase 3 trials of retatrutide, an investigational GLP-1, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and Type 2 diabetes – common obesity-related conditions.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,"...
In brief: CMS lifts claims hold, Eli Lilly drafts Shaq, Menlo Ventures surveys AI adoption
October 29, 2025HME News Staff
WASHINGTON – CMS has instructed all Medicare Administrative Contractors (MACs) to lift the claims hold and process claims with dates of service Oct. 1, 2025, and later for certain services impacted by select expired Medicare legislative payment provisions passed under the Full-Year Continuing Appropriations and Extensions Act of 2025.
This includes claims paid under the:
Medicare Physician Fee Schedule
Ground ambulance transport
Federally Qualified Health...
Eli Lilly, O’Neal 'break through stigma’ of obstructive sleep apnea
October 28, 2025HME News Staff
INDIANAPOLIS – Eli Lilly has a new partnership with NBA Hall of Famer and cultural icon Shaquille O’Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA).
The campaign aims to educate the public about symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity, the company says.
"Moderate-to-severe...
Eli Lilly says tirzepatide reduces OSA severity
June 24, 2024HME News Staff
INDIANAPOLIS – Eli Lilly’s tirzepatide demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo, according to the company’s SURMOUNT-OSA phase 3 clinical trials evaluating the drug for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, with and without CPAP therapy.
In a key secondary endpoint, the company...
Glooko, Eli Lilly to collaborate on connected insulin pens
May 7, 2021HME News Staff
GOTHENBURG, Sweden – Glooko will partner with Eli Lilly for a strategic digital health collaboration using Eli Lilly’s connected insulin pens, the Tempo Pen and Tempo Smart Button. Through the agreement, the Tempo Smart Button will pair with Glooko’s software to integrate personalized health care data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs. “Lilly is...